Novavax Inc (NVAX)
$49.64 3.18 (6.02%)
18:15 EDT NVAX Stock Quote Delayed 30 Minutes
Previous Close $52.82
Market Cap 18.95B
PE Ratio -81.38
Volume (Avg. Vol.) 6.53M
Day's Range 47.66 - 52.74
52-Week Range 3.54 - 61.50
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.
With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.
Uber, Novavax, DraftKings and Aurora Cannabis were our top stock trades for Wednesday. Let's have a look at what the charts say.
Novavax (NVAX) news for Tuesday concerning funding for a vaccine to stop the novel coronavirus has NVAX stock rocketing higher.
Novavax (NVAX) news for Wednesday concerning a trial for a vaccine to treat the coronavirus from China has NVAX stock flying high.
Investors began buying up NVAX shares in anticipation of the Phase 3 clinical trial announcement. We wound up with a 130% gain on the trade.
Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.
Novavax (NVAX) earnings for the vaccine company's fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday.
Tesla made its one-millionth car, while Delta expects to save $2 billion in fuel costs. Here's the stock market today.
By Ian Cooper
While most stocks and markets have taken big hits, these three coronavirus stocks have been among the most explosive opportunities.
Boeing shares tanked on more negative reports, while Uber rallied on an asset sale. Here's what happened in the stock market today.
Novavax (NVAX) news for Tuesday concerning the spread of a virus in China has NVAX stock heading higher as more investors pick up the stock.
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.
Novavax news for Thursday concerning an accelerated approval pathway for one of the company's drugs has NVAX stock soaring higher.
Novavax news concerning the results from the company's recent trail of its drug ResVax has NVAX stock falling on Thursday.
Novavax stock is plunging on Thursday after failing a Phase 3 study. That sets up a breakdown instead of a breakout in NVAX stock.
These penny stocks are well-positioned for improving market conditions and possibly growth beyond penny stock status in the second half of 2018 and beyond.
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut. Com....
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader